Semaglutide for weight loss: unanswered questions

Front Endocrinol (Lausanne). 2024 Jun 5:15:1382814. doi: 10.3389/fendo.2024.1382814. eCollection 2024.

Authors

Ploutarchos Tzoulis¹, Stephanie E Baldeweg²

Affiliations

¹ Department of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, London, United Kingdom.
² Division of Medicine, University College London, London, United Kingdom.

No abstract available

Keywords: GLP 1 analog; anti-obesity medications; obesity; overweight; semaglutide.

MeSH terms

Anti-Obesity Agents / pharmacology
Anti-Obesity Agents / therapeutic use
Glucagon-Like Peptides* / therapeutic use
Humans
Obesity / drug therapy
Semaglutide
Weight Loss* / drug effects

Substances

Glucagon-Like Peptides
Anti-Obesity Agents
Semaglutide